Clinical Trial Update: A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy and safety of bedtime TNX-102 SL for fibromyalgia has completed, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibromyalgia
• Myofascial Pain Syndrome

Drugs mentioned

• TNX-102 SL (cyclobenzaprine hydrochloride)

Snippet

Sponsor: Tonix Pharmaceuticals, Inc. | Conditions: Fibromyalgia, Myofascial Pain Syndromes | Phase 3 | Status: COMPLETED | Results posted: 2025-02-07